Marker Therapeutics (NASDAQ:MRKR) Announces Quarterly Earnings Results, Beats Expectations By $0.16 EPS

Marker Therapeutics (NASDAQ:MRKR) announced its quarterly earnings results on Friday. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.16, Zacks reports. Marker Therapeutics had a negative return on equity of 73.29% and a negative net margin of 343.03%.

Marker Therapeutics Trading Up 2.7%

NASDAQ MRKR opened at $1.14 on Friday. The stock has a market capitalization of $19.00 million, a price-to-earnings ratio of -2.78 and a beta of 1.50. The stock has a 50-day moving average of $1.32 and a 200 day moving average of $1.42. Marker Therapeutics has a twelve month low of $0.81 and a twelve month high of $2.46.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. Weiss Ratings cut shares of Marker Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, August 6th. HC Wainwright reiterated a “buy” rating on shares of Marker Therapeutics in a research note on Wednesday, May 20th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $10.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Osaic Holdings Inc. increased its holdings in Marker Therapeutics by 16.5% in the 4th quarter. Osaic Holdings Inc. now owns 94,421 shares of the company’s stock worth $141,000 after acquiring an additional 13,340 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Marker Therapeutics by 16.4% during the 4th quarter. Renaissance Technologies LLC now owns 123,650 shares of the company’s stock worth $184,000 after purchasing an additional 17,400 shares during the last quarter. Jane Street Group LLC purchased a new position in Marker Therapeutics in the 2nd quarter valued at about $33,000. LPL Financial LLC boosted its holdings in Marker Therapeutics by 41.7% in the 4th quarter. LPL Financial LLC now owns 83,247 shares of the company’s stock worth $124,000 after buying an additional 24,500 shares during the last quarter. Finally, Virtu Financial LLC acquired a new position in shares of Marker Therapeutics during the third quarter valued at approximately $25,000. Hedge funds and other institutional investors own 22.39% of the company’s stock.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.